1 Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
2 Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition, Paris, France.
3 Department of Medicine and Robert H Lurie Cancer Center, Northwestern University, Chicago, IL, USA.
4 AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition, Paris, France.
5 Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: [email protected].